김승택 (한국파스퇴르연구소) | 한빛사논문 > 한빛사

상위피인용논문

조회813

김승택Seungtaek Kim

한국파스퇴르연구소

CV File 639 kb

Antimicrob. Agents Chemother., 23 June 2020 | https://doi.org/10.1128/AAC.00819-20 Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Sangeun Jeon^a, Meehyun Ko^a, Jihye Lee^a, Inhee Choi^b, Soo Young Byun^c, Soonju Park^c, David Shum^c, and Seungtaek Kim^a

^aZoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea
^bMedicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea
^cScreening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea

Sangeun Jeon and Meehyun Ko contributed equally to this work.

Address correspondence to Seungtaek Kim

Abstract

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC₅₀s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.

논문정보

형식Research article
게재일2020년 06월 (BRIC 등록일 2022-02-07)
연구진국내 연구진
분야 생명과학 > 미생물학
피인용횟수60회 이상 인용된 논문

댓글 작성 로그인

CV 열람하기

연락처 보기